TJ037130 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug called TJ037130 in people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment is available. The drug targets a protein called Claudin 6 on tumor cells and may help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be physically able to perform daily activities (ECOG 0 or 1).
- Your tumor must have tested positive for Claudin 6 protein (by a lab test).
- You must have advanced cancer that has spread or come back, and standard treatments are no longer working or are not suitable.
- You must have at least one tumor that can be measured or evaluated by scans.
- You must not have had certain prior cancer treatments (like PD-1/PD-L1 inhibitors) within the last 28 days, and no prior treatments targeting Claudin 6 or 4-1BB.
- You must be willing to use effective contraception if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an investigational drug (AT03-65) for people with advanced solid tumors that have a certain protein called CLDN6. The goal is to see if the drug is safe and if it might help shrink tumors.
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
This trial tests a new type of cell therapy (CAR-T) that targets a protein called Claudin18.2 found on some stomach, esophagus, and gastroesophageal junction cancers. The goal is to see if this treatment can shrink tumors or stop them from growing when other treatments have stopped working.
This trial tests a new drug called LCB02A, which targets a protein called Claudin 18.2 found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.